Skip to main content

FDA Updates

FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas

Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer

Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer

Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML

Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation

Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation

Polivy Received New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma

Omisirge FDA Approved for Patients With Hematologic Malignancies to Reduce Time to Neutrophil Recovery and Infection

Padcev Plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma

1
2
3
4
5
6

Page 3 of 33
Results 21 - 30 of 330